AJANTA PHARMA
|
AJANTA PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 64.83 | 46.70 | 83.45 | 75.59 | 53.60 |
| CEPS(Rs) | 75.58 | 57.09 | 65.42 | 59.34 | 43.05 |
| DPS(Rs) | 51.00 | 7.00 | 9.50 | 9.50 | 13.00 |
| Book NAV/Share(Rs) | 282.89 | 269.07 | 382.20 | 346.24 | 297.80 |
| Tax Rate(%) | 26.73 | 21.10 | 21.64 | 27.36 | 29.56 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.69 | 10.93 | 27.37 | 33.85 | 26.40 |
| EBIT Margin(%) | 14.05 | 10.48 | 27.09 | 30.80 | 26.12 |
| Pre Tax Margin(%) | 13.96 | 10.40 | 26.78 | 30.52 | 25.66 |
| PAT Margin (%) | 10.23 | 8.20 | 20.99 | 22.17 | 18.07 |
| Cash Profit Margin (%) | 11.93 | 10.03 | 24.68 | 26.10 | 21.77 |
| Performance Ratios | |||||
| ROA(%) | 17.73 | 13.21 | 17.16 | 17.03 | 14.44 |
| ROE(%) | 23.49 | 17.68 | 22.77 | 23.38 | 19.32 |
| ROCE(%) | 32.22 | 22.57 | 29.37 | 32.20 | 27.44 |
| Asset Turnover(x) | 1.73 | 1.61 | 0.82 | 0.77 | 0.80 |
| Sales/Fixed Asset(x) | 3.42 | 3.19 | 1.56 | 1.44 | 1.46 |
| Working Capital/Sales(x) | 4.37 | 4.25 | 2.10 | 2.14 | 2.50 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.29 | 0.31 | 0.64 | 0.69 | 0.68 |
| Receivable days | 52.69 | 52.87 | 94.50 | 93.66 | 87.08 |
| Inventory Days | 37.60 | 40.91 | 83.71 | 78.09 | 65.68 |
| Payable days | 183.71 | 157.44 | 188.77 | 260.89 | 199.39 |
| Valuation Parameters | |||||
| PER(x) | 34.52 | 25.89 | 14.45 | 15.82 | 16.99 |
| PCE(x) | 29.61 | 21.18 | 18.44 | 20.15 | 21.16 |
| Price/Book(x) | 7.91 | 4.49 | 4.73 | 5.18 | 4.59 |
| Yield(%) | 2.28 | 0.58 | 0.53 | 0.53 | 0.95 |
| EV/Net Sales(x) | 6.66 | 3.98 | 4.56 | 5.30 | 4.54 |
| EV/Core EBITDA(x) | 22.32 | 16.89 | 14.58 | 14.94 | 15.16 |
| EV/EBIT(x) | 25.02 | 19.83 | 16.57 | 16.85 | 17.40 |
| EV/CE(x) | 7.86 | 4.39 | 3.63 | 3.72 | 3.29 |
| M Cap / Sales | 6.70 | 4.07 | 4.62 | 5.37 | 4.61 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.45 | 12.02 | 15.62 | 11.66 | 25.91 |
| Core EBITDA Growth(%) | 42.48 | -15.61 | 1.99 | 32.11 | 32.00 |
| EBIT Growth(%) | 49.27 | -18.33 | 1.24 | 34.41 | 31.13 |
| PAT Growth(%) | 38.81 | -17.50 | 8.99 | 39.81 | 20.86 |
| EPS Growth(%) | 38.81 | -44.04 | 10.40 | 41.02 | 20.86 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.02 |
| Current Ratio(x) | 3.04 | 2.48 | 3.50 | 2.64 | 2.39 |
| Quick Ratio(x) | 2.12 | 1.77 | 2.31 | 1.74 | 1.73 |
| Interest Cover(x) | 155.50 | 128.61 | 90.16 | 109.85 | 56.75 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of AJANTA PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AJANTA PHARMA | ₹35,479.1 Cr | -0.9% | -0.5% | 45% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,948.0 Cr | -0% | 0.5% | 46.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹157,873.0 Cr | -3% | 0.9% | 61.2% | Stock Analytics | |
| CIPLA | ₹116,809.0 Cr | -2.1% | -6.9% | 19.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,963.0 Cr | -0.6% | -3.3% | 7.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,173.2 Cr | -1.9% | 0.7% | 54.5% | Stock Analytics | |
AJANTA PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | -0.9% |
-0.5% |
45% |
| SENSEX | -0.6% |
2.3% |
16.9% |
You may also like the below Video Courses
